OXFORD, United Kingdom, May 19, 2022 — Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, announced titles of nine abstracts to be presented as oral presentations and posters at the International Society for Extracellular Vesicles (ISEV) Annual Meeting, on May 25 to 29, 2022, in Lyon, France. The oral presentations and … Read more
OXFORD, U.K. May 9, 2022 — Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, announced two oral presentations at the International Society for Cell & Gene Therapy (ISCT) 2022 Meeting, May 4 to 7, in San Francisco. The presentations were part of the ISCT 1-day Scientific Signature series “Therapeutic Advances with … Read more
OXFORD, United Kingdom, April 14, 2022 — Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, announces the appointment of Peter Jones as Vice President of CMC. “Peter has been at the forefront of developing bio manufacturing processes for many of the newest and most cutting-edge biotechnology platforms, including both lentiviral gene … Read more
Newly issued patent covers proprietary approach for loading nucleic acids into exosomes Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, today announced that the Company has been granted a new European patent, EP3706796, to add to its growing patent portfolio. This patent covers exosomes loaded with nucleic acids or ribonuclear protein … Read more
Evox’s engineered exosomes show better efficacy compared to conventional biologics and significantly outperformed other previously published exosome display platforms Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, announces that it has, in close collaboration with one of its co-founder’s lab at the Karolinska Institute, published a landmark paper in Nature Biomedical … Read more
Accolade recognises Evox’s efforts in developing a proprietary pipeline of exciting therapeutics based on exosome technology, a successful fundraising and transformative deals with Takeda and Eli Lilly Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, is pleased to announce that it has been awarded the Best Emerging Biotech Award at the … Read more
Evox data demonstrates the targeting and enhanced delivery of engineered exosomes using its proprietary DeliverEX platform Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, announces today that the company will present data at the 24th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), which is being held … Read more
Financing round significantly oversubscribed by both new and existing investors Proceeds enable advancement of our exosome therapeutics into the clinic and expansion of our world-leading exosome platform Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, today announces that it has raised £69.2 million ($95.4 million) in a Series C financing round. … Read more
Highly experienced life sciences executive that brings large pharma and biotech experience Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, today announces that John McHutchison has joined its Board of Directors. John will be joining the Board as the representative for Oxford Sciences Innovation (OSI), one of the Company’s major shareholders. … Read more
Grant protects a proprietary approach that enables luminal loading of soluble therapeutic proteins into exosomes Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, is pleased to announce that the Company has been granted another key patent by the European Patent Office (EPO). This new grant reinforces the Company’s leading position within … Read more